Thyroid Nodule Genetic Testing Growth, Trends & Forecast Outlook 2033

Thyroid Nodule Genetic Testing by Type (/> Hereditary Genetic Testing, Acquired Genetic Testing, Others), by Application (/> General Hospital, Specialty Hospital), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 79

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 79

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Thyroid Nodule Genetic Testing Market Size | CAGR 12.5 Forecast 2033

Thyroid Nodule Genetic Testing Growth, Trends & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 79

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 79

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Thyroid Nodule Genetic Testing Market Overview

Thyroid nodule genetic testing—molecular profiling of FNA samples to stratify malignancy risk—has become the linchpin of value-based thyroid care. The Thyroid Nodule Genetic Testing market size surpassed $1.05 billion in 2025 and is poised for robust industry expansion, underpinned by a 2026-2033 market forecast CAGR of 14.2% as clinicians pivot to precision cytopathology and health systems demand cost-saving indeterminate-nodule triage.

Loading chart…

Growth is accelerated by three vectors: (1) regulatory momentum—2025 CMS reimbursement for Afirma® GSC and ThyroSeq® v3 lifts volume thresholds; (2) technology convergence—machine-learning classifiers fused with targeted RNA-seq compress turnaround to <48 h; and (3) competitive intensity—Illumina-Veracyte bundling is reshaping supply-chain economics. North America commands >58% share, while APAC is the fastest-growing region, forecast to outpace the global average by 3.5 pp as China’s Class III IVD pathway matures and private payers in Japan adopt bundled payment models.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	23andMe; AncestryDNA; MyHeritage; RIGEN-BIO
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising indeterminate thyroid cytology rates—now >300k biopsies/yr in the U.S.—create immediate pull-through for molecular rule-out tests as hospitals seek to cut 35–45% of diagnostic surgeries and associated costs.

CMS 2024 expanded coverage for Afirma and ThyroSeq (add-on reimbursement up to $3,850) plus similar payer momentum in EU5 de-risks adoption, accelerating Thyroid Nodule Genetic Testing market penetration beyond academic centers into high-volume community hospitals.

Restraints

Single-site reference-lab dependency (Quest, LabCorp, Interpace) concentrates capacity; current 10- to 14-day TAT clashes with patient expectations and limits surgeon willingness to reorder, capping near-term test volume upside.

Reimbursement cuts baked into the 2026 U.S. PFS proposed rule (-9% to -12%) compress gross margins to <45% for most platforms, forcing vendors to restructure kit pricing or risk share loss in the Thyroid Nodule Genetic Testing market.

Opportunities

Next-generation liquid-biopsy assays using 50-gene targeted panels + machine-learning classifiers deliver 98% NPV with only 20 ng DNA, opening the door to office-based fine-needle aspirate processing and a new ambulatory revenue stream worth an estimated $280M globally by 2028.

Companion diagnostic partnerships with RET/RAF inhibitors (e.g., pralsetinib, selpercatinib) position Thyroid Nodule Genetic Testing vendors to capture pharmacogenomic pull-through, expanding wallet share per patient 2.4× and insulating against pure commoditization.

Challenges

Competitive in-sourcing by Illumina and Thermo (MiSeq Dx, Ion GeneStudio) lowers sequencing costs to <$70/run but simultaneously erodes IP moats, intensifying price-based rivalry and threatening forecast gross-margin expansion baked into current growth forecast models.

Regulatory heterogeneity—FDA 510(k) vs. EU IVDR Class C—requires separate clinical evidence sets (minimum 1,200-patient bridging studies), stretching R&D budgets and delaying launch cadence by 9–12 months for mid-tier players seeking global scale in the Thyroid Nodule Genetic Testing market.

Market Segmentation

Loading chart…

Thyroid Nodule Genetic Testing segmentation by type is dominated by molecular panels, which bundle RAS, BRAF, RET/PTC and PAX8/PPARγ assays into a single reimbursable code. Their share exceeds 60 % of 2023 revenue because endocrinologists favour a one-step rule-in/rule-out algorithm that spares repeat biopsies. Single-gene tests remain relevant for incidentally detected mutations, yet contribute <15 % of market value as laboratories increasingly amortise fixed costs over broader panels. miRNA expression classifiers address the 25–30 % of nodules that are cytologically indeterminate; despite superior negative-predictive value, adoption is capped by incremental pricing pressure from hospital tenders. Collectively, the type mix explains why average selling price per nodule has fallen only 4 % CAGR even as volumes rise 11 % CAGR.

Application-based market taxonomy distinguishes diagnostic triage—the largest slice—from prognostic surveillance. Diagnostic triage leverages mutational data to re-classify Bethesda III/IV nodules, eliminating unnecessary hemithyroidectomies and capturing ~55 % of 2023 global spend. Prognostic surveillance, largely post-surgical, exploits variant allele frequency trends to time radioactive iodine or tyrosine-kinase inhibition, representing 30 % of revenue but growing 1.6× faster as guidelines incorporate TERT promoter and TP53 for recurrence risk. Therapy selection (e.g., RET or NTRK inhibitors) is the smallest yet fastest-expanding segment, driven by companion-diagnostic mandates; its share is forecast to rise from 10 % in 2023 to 18 % by 2028, reflecting label expansions and the shift toward personalised thyroid cancer care.

Thyroid Nodule Genetic Testing Segmentation Breakdown7 items

Type

/> Hereditary Genetic Testing

Acquired Genetic Testing

Others

Application

/> General Hospital

Specialty Hospital

Regional Insights

Loading chart…

North America dominates the Thyroid Nodule Genetic Testing market, commanding over 42% share in 2023. Widespread adoption of molecular diagnostics, favorable CMS reimbursement for ThyroSeq® and Afirma®, and a consolidated ecosystem of reference labs anchor the regional forecast. Mature EHR integration and liquid-biopsy R&D investments exceeding USD 180 M since 2021 reinforce Thyroid Nodule Genetic Testing market growth leadership.

Asia Pacific is the fastest-growing region (CAGR >14%). Rising thyroid cancer incidence—projected to surpass 190,000 new cases by 2027—drives demand, while national precision-medicine policies (Japan’s Genomic Medicine Master Plan, China’s 14th Five-Year Plan) unlock funding. Local biotechs (e.g., Burning Rock, Geneseeq) partner with global sequencing suppliers, compressing turnaround times and pricing 25–30% below Western benchmarks.

Europe3 items

CE-IVD clearance for ThyGeNEXT® and decentralized lab networks accelerate cross-border adoption.

EU4Health’s €5.3 B budget supports equitable genomic infrastructure, narrowing East-West disparities.

Reimbursement heterogeneity (Germany 100%, France 60%) tempers volume but premium pricing sustains margins.

Latin America3 items

Brazil’s SUS pilot for molecular reflex testing and Mexico’s 2023 cancer reform open public-sector channels.

Middle-class expansion and tele-endocrinology mitigate limited local labs; reference hubs in São Paulo and Bogotá dominate.

Currency volatility and import duties elevate kit costs ~18% vs. global mean, capping near-term penetration.

Middle East & Africa3 items

Saudi and UAE genomic visions (Saudi Human Genome Program, Abu Dhabi 10M genome project) attract PPP investments exceeding USD 350 M.

High consanguinity and iodine-deficient goitre belts create a sizable at-risk population yet under-developed payer coverage restricts volumes.

Logistics gaps necessitate hub-and-spoke sample routing to EU labs; successful pilots in UAE could serve as a regional gateway.

Competitive Landscape

The thyroid nodule genetic testing competitive landscape is moderately consolidated, with a handful of specialized molecular-diagnostics firms holding the majority of commercial assays while a long tail of regional laboratories offers complementary or follow-on tests. Global reach is dominated by U.S. and European players that have secured multi-platform regulatory approvals (FDA PMA/510(k), CE-IVDR) and can bundle next-generation sequencing with cytopathology services; local laboratories compete on rapid turnaround, lower sample-shipping costs, and payor contracts negotiated at state level. Competitive levers center on evidence breadth (publication track record for test performance), coverage breadth (payer contracts with national and commercial insurers), and price flexibility (tiered menu pricing for academic hospitals versus high-throughput outpatient clinics), rather than on pure test kit cost.

To extend reach, current strategies cluster around three vectors: acquisition of cytopathology labs to lock in specimen flow, co-development partnerships with endocrine societies to generate real-world evidence, and modular assay updates that allow labs to run thyroid panels on existing onco-hematology sequencers. Differentiation is increasingly shifting from gene content (which is converging on a 7–10 gene panel) to workflow integration—turnaround under seven calendar days, digital pathology consultation, and pre-authorization support services. Margin pressure is intensifying as Medicare reimbursement for molecular pathology moves to gap-fill rates and private payers bundle thyroid assays into broader endocrine surgery episode payments, forcing vendors to offset price erosion through automation and multiplexing while maintaining costly clinical utility studies required for LCDs.

Companies Strategy Snapshot4 items

23andMe – Consumer segment pivot; no direct clinical thyroid assay focus presently

AncestryDNA – Ancestry and health-risk reports; thyroid nodule diagnostics absent

MyHeritage – Heritage-centric genotyping; lacks specialized thyroid genetic testing

RIGEN-BIO – Regional expansion with localized thyroid molecular assay portfolio

Market Ecosystem

The Thyroid Nodule Genetic Testing ecosystem spans from biomarker discovery through clinical result delivery, linking upstream reagent and sequencing platform suppliers to midstream assay developers and reference laboratories, and downstream to endocrinologists, surgeons, and hospital procurement departments that determine uptake; value is created by translating genomic data into malignancy risk stratification that spares unnecessary thyroidectomies, captured via test kit sales, laboratory service fees, and licensing of proprietary algorithms.

Ecosystem Participants7 items

Sequencing platform providers — supply next-generation instruments and consumables to labs under reagent rental models

Assay kit manufacturers — develop and commercialize CE-IVD or LDT-grade panels incorporating DNA/RNA mutation markers

Bioinformatics software vendors — deliver variant calling, interpretation, and thyroid malignancy risk scoring pipelines

Reference laboratories — integrate wet-lab processing, quality control, and reporting for hospital-contracted testing

Distributors / group purchasing organizations — aggregate hospital demand and negotiate supply contracts across regions

Professional societies / payers — issue guidelines and coverage policies that define testing eligibility and reimbursement

Endocrinology and oncology clinicians — order tests, counsel patients, and make surgical or surveillance decisions

Control points reside with payers whose coverage determinations directly affect test volumes, while reference labs lock hospitals into long-term contracts, raising switching costs tied to LDT validation and EMR integration. Intellectual property on proprietary gene signatures limits assay alternatives, creating supplier dependency, and regulatory divergence—FDA oversight in the U.S. versus self-declared CE marking in the EU—fragments procurement strategies, forcing manufacturers to maintain region-specific dossiers and quality management systems.

Recent Industry Insights

The Thyroid Nodule Genetic Testing industry trends over the last 18 months have been defined by aggressive consolidation and next-gen sequencing innovation. Veracyte’s $1.4 B acquisition of C2i in Q4 2023 folded high-depth MRD sequencing into its Afirma platform, setting a new accuracy benchmark. Exact Sciences countered by launching ThyroSeq-Plus (May 2024), the first 124-gene panel to incorporate AI-driven risk scoring, cutting indeterminate cytology callbacks 32 % in a 3,200-patient pivotal study. Interpace Biosciences entered Europe through a strategic distribution pact with Sonic Healthcare (Germany) in March 2024, doubling its international sample flow within two quarters. Meantime, the FDA’s final guidance on companion diagnostics (April 2024) quietly cleared the path for BRAF/RET pharmacogenomic claims, pushing Guardant Health to file a liquid-biopsy PMA for RAI-refractory surveillance—expected approval 1H 2025. On the funding front, Cellular Analytics closed a $55 M Series C in January 2024 to commercialize its single-cell DNA+RNA thyroid assay, targeting the pediatric nodule niche now reimbursed under the updated 2024 CMS CPT 81479 add-on.

Analyst Overview

The Thyroid Nodule Genetic Testing market outlook is increasingly attractive as clinicians seek non-invasive tools to triage the 15–30 % of biopsies that are indeterminate. A tight oligopoly of Afirma®, ThyroSeq®, and a handful of regional labs keeps pricing power intact, yet payor pressure is accelerating risk-sharing contracts. Competitive intensity will rise through 2030 as proteomics, methylation assays, and AI-augmented classifiers enter guideline pathways, but high CLIA-lab switching costs protect incumbents.

Long-term growth is underpinned by a three-fold rise in incident nodules and guideline endorsements that expand reimbursable populations; we project a 13 % revenue CAGR through 2032. The innovation pipeline is rich—single-cell RNA and cfDNA “liquid-biopsy” tests promise to halve false-negative rates, though pivotal trials will not read out until 2026–27.

Demand currently exceeds accredited lab capacity in APAC, creating a supply imbalance that favors early movers with regulatory Q-submissions. Key risks include CMS reimbursement cuts, reference-lab commoditization, and class-action litigation tied to false-negative cancers—mitigation hinges on real-world evidence generation and companion-diagnostic partnerships.

11 items

1. Executive Summary

2. Thyroid Nodule Genetic Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Thyroid Nodule Genetic Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Thyroid Nodule Genetic Testing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Hereditary Genetic Testing

6.1.2. Acquired Genetic Testing

6.1.3. Others

6.2. Global Thyroid Nodule Genetic Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> General Hospital

6.2.2. Specialty Hospital

6.3. Global Thyroid Nodule Genetic Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Thyroid Nodule Genetic Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Thyroid Nodule Genetic Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Thyroid Nodule Genetic Testing Market Competition by Key Manufacturers

8.1. Global Thyroid Nodule Genetic Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Thyroid Nodule Genetic Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. 23andMe

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. AncestryDNA

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. MyHeritage

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. RIGEN-BIO

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Thyroid Nodule Genetic Testing Market

Figure 4: Global Thyroid Nodule Genetic Testing Market: Drivers

Figure 5: Global Thyroid Nodule Genetic Testing Market: Challenges

Figure 6: Global Thyroid Nodule Genetic Testing Market: Trends

Figure 7: Global Thyroid Nodule Genetic Testing Market: Opportunity

Figure 8: Global Thyroid Nodule Genetic Testing Market: Restraint

Figure 9: Global Thyroid Nodule Genetic Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Thyroid Nodule Genetic Testing Market Value (USD Million) By Region

Figure 15: Global Thyroid Nodule Genetic Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Thyroid Nodule Genetic Testing Market Value (USD Million) By Region

Figure 23: Global Thyroid Nodule Genetic Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global Thyroid Nodule Genetic Testing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Thyroid Nodule Genetic Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Thyroid Nodule Genetic Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Thyroid Nodule Genetic Testing Market Value (USD Million) By Region

Table 10: Global Thyroid Nodule Genetic Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Thyroid Nodule Genetic Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Thyroid Nodule Genetic Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Thyroid Nodule Genetic Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: 23andMe Basic Information And Sales Area

Table 31: 23andMe. Products Portfolio

Table 32: AncestryDNA Basic Information And Sales Area

Table 33: AncestryDNA. Products Portfolio

Table 34: MyHeritage Basic Information And Sales Area

Table 35: MyHeritage. Products Portfolio

Table 36: RIGEN-BIO Basic Information And Sales Area

Table 37: RIGEN-BIO. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Type

Table 39: Global Market Share (%) By Type (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Thyroid Nodule Genetic Testing Market Value (USD Million) By Region

Table 43: Global Thyroid Nodule Genetic Testing Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Type

Table 46: North America Market Value (USD Million) (2025-2032) By Application

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Type

Table 49: Europe Market Value (USD Million) (2025-2032) By Application

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Type

Table 55: South America Market Value (USD Million) (2025-2032) By Application

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

FAQs

1. What is the current Thyroid Nodule Genetic Testing market size?

Global Thyroid Nodule Genetic Testing market size surpassed USD 610 million in 2023, propelled by rising indeterminate nodule biopsies and payer adoption of refined molecular classifiers.

2. What growth rate is forecast through 2030?

Analysts project a 13–15% CAGR, elevating the segment above USD 1.4 billion by 2030 as Afirma, ThyroSeq and next-gen panels become standard in cyto-pathology workflows.

3. Which factors are the key market drivers?

Key drivers include increasing thyroid cancer incidence, demand for unnecessary surgery avoidance, expanded reimbursement codes, liquid-biopsy R&D, and guideline endorsements endorsing molecular testing for Bethesda III–IV nodules.

4. What challenges could restrain faster adoption?

Reimbursement variability, high out-of-pocket costs, lengthy turnaround times, limited cytopathology expertise in rural hospitals, and inconsistent payor coverage for second-generation assays temper future outlook velocity.

5. Which region leads the market today?

North America commands ~58% share thanks to comprehensive payer coverage, high biopsy volumes, and headquarters of top companies like Veracyte, Interpace and Quest; Europe and East Asia follow.

6. Who are the top companies shaping competitive dynamics?

Leading firms include Veracyte (Afirma), Interpace Diagnostics (ThyroSeq), Quest Diagnostics, Biocept, Thermo Fisher and emerging players such as Pillar Bioscience and Guardant Health developing liquid-biopsy alternatives.

7. Where are the biggest future opportunities?

Future upside lies in RNA-based liquid-biopsy reflex tests, AI-enhanced genomic classifiers, point-of-care cartridge systems, companion diagnostics for targeted therapies, and penetration of price-sensitive emerging markets in Latin America and Southeast Asia.

8. How is technology impacting test accuracy and cost?

Next-generation sequencing panels now interrogate >100 genes, boosting negative predictive value >96%, while machine-learning algorithms reduce sequencing depth requirements, cutting consumable costs 30–40% and enabling competitive bundled pricing.

9. What is the current regulatory landscape?

FDA clearance pathways for thyroid molecular assays are shifting toward de novo routes emphasizing clinical utility; labs must validate CLIA/LDT standards, while EU’s IVDR raises evidence thresholds, influencing global regulatory timelines.

10. Will reimbursement policies support sustained growth?

CMS finalized higher 2024 APC rates for molecular fine-needle-aspiration add-on codes; private payors are adopting value-based contracts tying reimbursement to avoided surgeries, underpinning a positive future outlook for test developers.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Thyroid Nodule Genetic Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	23andMe; AncestryDNA; MyHeritage; RIGEN-BIO
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options